Examiner. Withdrawal of all rejections and reconsideration of the amended claims is requested. An early allowance is earnestly sought.

Respectfully submitted,

Dated: September 10, 2003

Carmella L. Stephens
Patent Office Reg. No. 41,328

BAKER BOTTS L.L.P. 30 Rockefeller Plaza New York, New York 10112-0228

Attorneys for Applicants (212) 408-2500

APPENDIX A

IN THE CLAIMS:

Please cancel claims 4-6 and 20-27, without prejudice.

Please insert the following new claims:

---28. (new) A method for activating an imidazoline receptor expressed in a cell comprising contacting said cell with an imidazoleacetic acid-ribotide.

- 29. (new) A method for activating an imidazoline receptor expressed in a cell comprising contacting said cell with an imidazoleacetic acid-riboside.
- 30. (New) The method of claim 28 or 29 wherein the methylene group is substituted for the oxygen atom that links the 5' carbon to the phosphate atom in the imidazoleacetic acid-ribotide.
- 31. (New) The method of claim 28 or 29 wherein the imidazoleacetic acid-ribotide is a 2' or 3' deoxy-IAA-RP.
- 32. (New) The method of claim 28 or 29 wherein the imidazoleacetic acid-ribotide is a carboxy-methyl or carboxy-ethyl ester of IAA-RP.
- 33. (New) The method of claim 28 or 29 wherein furan is linked to the number 2 carbon atom of the imadazole ring.

- 34. (New) The method of claim 28 or 29 wherein furan is linked to the nitrogen closest to the methylene-carboxy side chain of the imidazole ring.
- 35. (New) The method of claim 28 or 29 wherein the imadazole ring is converted to an imadzoline ring.
- 36. (New) The method of claim 28 or 29 wherein the activation of the imidazoline receptor results in release of arachidonic acid from said cell.
- 37. (New) The method of claim 28 or 29 wherein the acitvation of the imidazoline receptor results in release of insulin from said cell.
- 38. (New) The method of claim 28 or 29 wherein the activation of the imidazoline receptor results in release of catecholamines from said cell.---